Direct Pharmacokinetic Interaction Between Trintellix and Bupropion
Yes, Trintellix (vortioxetine) and bupropion do interact pharmacokinetically, but this interaction is clinically manageable and does not preclude their combined use. When co-administered, bupropion increases vortioxetine exposure by approximately 28% (AUC) and 14% (Cmax), which may require dose adjustment of vortioxetine 1.
Mechanism of Interaction
Bupropion acts as a CYP2D6 inhibitor, and since CYP2D6 is the primary enzyme metabolizing vortioxetine, co-administration reduces vortioxetine clearance 2, 3. This is a one-directional interaction—vortioxetine does not affect bupropion levels 1, 2.
Critical Context: Apalutamide Complicates This Picture
In your 72-year-old patient on apalutamide, there's a major confounding factor: apalutamide is a strong CYP3A4 inducer that dramatically reduces levels of CYP3A4 substrates by up to 92% 4, 5.
Impact on Vortioxetine:
- Vortioxetine is metabolized by multiple CYP enzymes including CYP3A4/5 1
- When co-administered with rifampicin (a broad CYP inducer similar to apalutamide), vortioxetine AUC decreased by 72% and Cmax by 51% 2
- The apalutamide-induced reduction in vortioxetine levels will likely overwhelm the bupropion-induced increase, resulting in net subtherapeutic vortioxetine concentrations
Impact on Bupropion:
- Bupropion is metabolized by CYP2B6 1, 6
- Apalutamide induces multiple CYP enzymes including CYP2B6 4
- Expect significantly reduced bupropion efficacy due to apalutamide-mediated enzyme induction
Practical Management Algorithm
Step 1: Anticipate the net effect
- Apalutamide will reduce both vortioxetine and bupropion levels substantially
- The bupropion-vortioxetine interaction becomes clinically insignificant in this context
Step 2: Dose adjustments
- Vortioxetine: Consider increasing to the maximum dose of 20 mg daily, monitoring closely for inadequate antidepressant response 2, 3
- Bupropion: May require dose escalation beyond typical ranges; monitor therapeutic response rather than relying on standard dosing
Step 3: Monitor for treatment failure
- Watch for breakthrough depressive symptoms indicating subtherapeutic drug levels
- Consider alternative antidepressants less dependent on CYP metabolism if inadequate response occurs
Additional Considerations
Alcohol Use
The intermittent binge alcohol use is a critical safety concern with bupropion, which lowers seizure threshold. This risk is independent of the drug-drug interactions discussed 7.
Alternative Strategy
Given the complex polypharmacy and strong CYP induction by apalutamide, consider:
- Antidepressants with minimal CYP metabolism (e.g., escitalopram, sertraline at higher doses)
- Mirtazapine, which has faster onset than SSRIs and different metabolic pathways 7
The combination of vortioxetine and bupropion is pharmacokinetically feasible in isolation, but apalutamide's potent enzyme induction makes both antidepressants likely to be subtherapeutic at standard doses in this specific patient.